Affimed

Affimed NV engages in the discovery and development of cancer immunotherapies. It is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The company’s proprietary ROCK platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs. The ROCK platform predictably generates customized innate cell engager molecules, which use patient's immune cells to destroy tumor cells. The company was founded in 2000 and is headquartered in Heidelberg, Germany.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Affimed reports Q1 loss, positive clinical data in cancer treatments

Affimed's Q1 2024 performance showed a net loss but highlighted positive clinical data and progress in cancer treatments.
Despite enrollment delays in the LuminICE trial, Affimed's programs leveraging the innate immune system demonstrate consistency and success.
Addressing financial challenges, patient enrollment issues, and leveraging opportunities in future study phases and partnerships are key for Affimed's growth.

Affimed reports Q3 performance, highlights clinical milestones, and eyes partnerships

Affimed's Q3 2024 performance reflects a net loss of EUR 15.1 million but maintains a solid cash position of EUR 24.1 million.
Management's focus on clinical milestones, safety profiles, and upcoming updates at ASH 2024 demonstrates a commitment to innovation.
Challenges lie in meeting data expectations, navigating partnerships, and balancing financial stability with growth aspirations.
Opportunities abound in showcasing progress at ASH 2024, exploring partnerships, and advancing clinical programs for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Affimed NV is a clinical-stage immuno-oncology company, which engages in the discovery and development of cancer immunotherapies. The company’s proprietary ROCK platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs. It operates through the Germany and USA geographical segments. The company was founded in 2000 and is headquartered in Mannheim, Germany.

MANNHEIM, Germany, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today presented a poster at the annual meeting of the Society for Immunotherapy of Cancer (SITC), indicating the Company's ICE® improves cytotoxicity of NK and CAR-NK cells and that NK cells redirected by ICE® exhibit at least the same efficacy against tumor cells as CAR-NK cells alone or redirected by the ICE®. The results emerged from a collaboration with the Fraunhofer Institute for Cell Therapy and Immunology (IZI) in Leipzig, Germany.

Affimed Presents Preclinical Data Showing that Addition of an Innate Cell Engager to NK and CAR-NK Cells Improves Tumor Cytotoxicity of Both Cell Types at the 38th Annual Meeting of the Society for Immunotherapy of Cancer

MANNHEIM, Germany, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced two upcoming presentations on its lead innate cell engager (ICE®) AFM13 at the American Society of Hematology (ASH) 2023 Annual Meeting.

Affimed Announces Oral Presentation of Phase 1/2 Data from AFM13 in Combination with Allogeneic NK Cells at the 2023 ASH Annual Meeting

MANNHEIM, Germany, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that the Company's management will participate in the following investor conferences during the month of November 2023.

Affimed to Participate in Upcoming Investor Conferences

Affimed N.V. (AFMD) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it.

Down -26.45% in 4 Weeks, Here's Why Affimed N.V. (AFMD) Looks Ripe for a Turnaround

MANNHEIM, Germany, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it has received approval from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) to transfer the listing of its shares from the Nasdaq Global Market to the Nasdaq Capital Market. This transfer is effective as of the opening of business on October 4, 2023.

Affimed Announces Listing Transfer to Nasdaq Capital Markets

MANNHEIM, Germany, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that an abstract with a comparison of NK cell redirected by the Company's innate cell engagers (ICE®) versus CAR-NK cells has been accepted for poster presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), which will be held on November 1-5, 2023 in San Diego, California.

Affimed Announces Acceptance of an Abstract Comparing NK Cells Redirected by Innate Cell Engagers and CAR-NK Cells for Poster Presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer

MANNHEIM, Germany, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that its Chief Financial Officer, Angus Smith, will participate in a fireside chat at the Cantor Global Healthcare Conference 2023 on Thursday, September 28, 2023 at 1:15 p.m. Eastern Daylight Time / 19:15 Central European Time.

Affimed to Present at the Cantor Global Healthcare Conference 2023

Avalo Therapeutics

ZyVersa Therapeutics Inc

Due to its low price, penny stocks may seem like a good place to invest your money. But they come with high risk.

3 penny stocks to buy under $1 in September

MANNHEIM, Germany, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that the FDA has granted fast track designation to the combination of its innate cell engager (ICE®) AFM13 with AlloNK® for the potential treatment of relapsed/refractory (r/r) Hodgkin lymphoma (HL). The combination treatment is entering Phase 2 development and will be investigated in Affimed's LuminICE-203 study (NCT05883449), which received IND-clearance earlier this year; the study also includes an exploratory cohort of CD30-positive peripheral T-cell lymphoma patients.

Affimed Receives FDA Fast Track Designation for AFM13 in Combination with AlloNK® for the Treatment of Patients with Relapsed or Refractory Hodgkin Lymphoma

HEIDELBERG, Germany, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that its Chief Executive Officer, Dr. Adi Hoess, will present at the H.C. Wainwright 25th Annual Global Investment Conference on Tuesday, September 12, 2023 at 11:00 a.m. Eastern Daylight Time / 17:00 Central European Time.

Affimed to Present at the H.C. Wainwright Annual Global Investment Conference

Cumulus Media

Information Services Group

Although relative few investors – let alone analysts hired by top research institutions – give much thought to low-volume speculative securities, the concept of top Wall Street penny stocks is not quite an oxymoron. Believe it or not, some market ideas are so compelling that they represent approved penny stock picks.

Surprise! These 3 Penny Stocks Have Wall Street's Seal of Approval.

HEIDELBERG, Germany, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced the publication of a manuscript that demonstrates how the FcRn-pH-HPLC technology can be leveraged to predict PK properties of various ICE® formats built on the ROCK® platform.

Affimed Announces Publication in the Journal mAbs on Leveraging FcRn-pH-HPLC as a Method to Select Bispecific Antibodies with Optimal Developability

Affimed N.V. (NASDAQ:AFMD ) Q2 2023 Earnings Call Transcript August 10, 2023 8:30 AM ET Company Participants Alex Fudukidis - Director of Investor Relations Adi Hoess - Chief Executive Officer Andreas Harstrick - Chief Medical Officer Angus Smith - Chief Financial Officer Wolfgang Fischer - Chief Operating Officer Arndt Schottelius - Chief Scientific Officer Conference Call Participants Maurice Raycroft - Jefferies Daina Graybosch - Leverink Partners Li Watsek - Cantor Fitzgerald Yale Jen - Laidlaw & Co Yanan Zhu - Wells Fargo Securities Srikripa Devarakonda - Truist Securities Andy Chen - Berenberg Operator Good day, everyone, and welcome to Affimed's Second Quarter 2023 Earnings and Corporate Update Call.

Affimed N.V. (AFMD) Q2 2023 Earnings Call Transcript

Affimed N.V. (AFMD) came out with a quarterly loss of $0.22 per share in line with the Zacks Consensus Estimate.

Affimed N.V. (AFMD) Reports Q2 Loss, Misses Revenue Estimates

HEIDELBERG, Germany, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today reported financial results and provided an update on clinical and corporate progress for the second quarter of 2023.

Affimed Reports Second Quarter 2023 Financial Results and Highlights Operational Progress

Ostin Technology Group Co Ltd

Sigma Labs Inc

The world of penny stocks is rife with potential pitfalls to avoid. Many firms trading at those prices are manipulated by actors with bad intent.

3 Cheap Stocks to Buy Under $1 in August 2023

HEIDELBERG, Germany, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release second quarter 2023 results and corporate update on Thursday, August 10, 2023. The Company will host a conference call at 8:30 a.m. EDT / 14:30 CET.

Affimed to Report Second Quarter 2023 Financial Results & Corporate Update on August 10, 2023

HEIDELBERG, Germany, July 31, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that an abstract with clinical trial results of its innate cell engager (ICE®) AFM24 in combination with NKGen Biotech's SNK01 (autologous non-genetically modified NK cells), has been accepted for a poster presentation at the ASCO Breakthrough conference from 3-5 August 2023 in Yokohama, Japan. The presentation includes dose escalation phase data on safety and efficacy of the phase 1 study in patients with advanced or metastatic EGFR-expressing solid tumors (NCT05099549).

Affimed Announces an ASCO Breakthrough Poster Presentation with Clinical Data of AFM24 in Combination with NKGen Biotech's SNK01 NK Cells

HEIDELBERG, Germany, June 22, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced the appointment of Dr. Constanze Ulmer-Eilfort to its Supervisory Board. Dr. Ulmer-Eilfort's appointment was approved during the Annual General Meeting of Shareholders which took place on June 21, 2023.

Affimed Announces Addition of Dr. Constanze Ulmer-Eilfort to its Supervisory Board

HEIDELBERG, Germany, June 09, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that two abstracts have been accepted for presentation at the 17th International Conference on Malignant Lymphoma (17-ICML) taking place in Lugano, Switzerland on June 13-17, 2023. A poster presentation will share a preclinical data set of Affimed's innate cell engager (ICE®) AFM13 in combination with Artiva Biotherapeutics Inc.'s (“Artiva”) off-the-shelf NK cell AB-101. An additional encore oral presentation will show the final results of the phase 2 REDIRECT study with AFM13 monotherapy in a r/r PTCL patient population.

Affimed Announces Acceptance of Abstracts at the 17th International Conference on Malignant Lymphoma (17-ICML)

HEIDELBERG, Germany, June 03, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced the presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting of safety and efficacy data from the EGFR mutant NSCLC expansion cohort of its ongoing phase 1/2 study investigating innate cell engager (ICE®) AFM24 as monotherapy. The data included 15 evaluable patients and showed encouraging early signs of clinical activity including confirmed partial responses and durable stable disease. EGFR mutant NSCLC is a very aggressive and resistant tumor type in which most classical NSCLC treatments achieve limited to no clinical activity, especially in more advanced patients. Affimed's innate cell engager AFM24 aims to reactivate the innate and consequently the adaptive immune system to recognize and destroy EGFR mutant tumors.

Affimed Presents AFM24 Monotherapy Data in Non-Small Cell Lung Cancer at the Annual Meeting of the American Society of Clinical Oncology and Provides Strategic Update on AFM24 Development Plan

HEIDELBERG, Germany, May 30, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that its Chief Executive Officer, Dr. Adi Hoess, will present at the 2023 Jefferies Healthcare Conference on Wednesday, June 7, 2023 at 8:30 a.m. Eastern Daylight Time / 14:30 Central European Time.

Affimed to Present at the 2023 Jefferies Healthcare Conference

HEIDELBERG, Germany, May 25, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed,” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced the publication of two abstracts with its innate cell engager (ICE®) AFM24 in advance of the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place on June 2 - 6, 2023 in Chicago, IL.

Affimed Announces Publication of AFM24 Clinical Abstracts for the Annual Meeting of the American Society of Clinical Oncology

Immutep Ltd

mCloud Technologies Corp

Opendoor

Palisade Bio

Are you new to penny stocks? Do you want to know how to use momentum and stock market volatility to your advantage?

Best Penny Stocks To Buy Now? 5 to Watch Under $5 This Week

Affimed N.V. (NASDAQ:AFMD ) Q1 2023 Earnings Conference Call May 23, 2023 8:30 AM ET Company Participants Alex Fudukidis - Director of Investor Relations Adi Hoess - Chief Executive Officer Andreas Harstrick - Chief Medical Officer Angus Smith - Chief Financial Officer Wolfgang Fischer - Chief Operating Officer Arndt Schottelius - Chief Scientific Officer Conference Call Participants Maurice Raycroft - Jefferies Li Watsek - Cantor Fitzgerald Srikripa Devarakonda - Truist Securities Bradley Canino - Stifel Yale Jen - Laidlaw Yanan Zhu - Wells Fargo Securities Operator Good day, everyone and welcome to Affimed's First Quarter 2023 Earnings and Corporate Update Call.

News for Affimed Stock (AFMD)